HLA-A68 and HLA-B15 alleles correlate with poor immune response among AIDS patients on combined antiretroviral therapy

Hum Immunol. 2016 Jun;77(6):490-7. doi: 10.1016/j.humimm.2016.04.009. Epub 2016 Apr 8.

Abstract

Around 15-30% of AIDS patients fail to recover their CD4(+) T cell levels following combined antiretroviral therapy despite successful inhibition of HIV-1 replication. The exact reasons for this immune recovery failure are not completely understood. HLA alleles are among the candidate that may explain this failure. A total of 65 adult AIDS patients, with viral load of <50 copies per ml were investigated. Viral load and CD4 T cells counts were performed following standard techniques. HLA genotyping was performed using PCR-SSP technique. The Statistical Package for Social Sciences (SPSS version 19) was used for data processing and analysis. A significantly higher proportion of poor immune responders were carrying HLA-A68 (4.8% compared to 25.0%, P=0.025) and HLA-B15 (2.4% compared to 20.8%, P=0.023). The etiological fraction (Efe%) among carriers of HLA-A68 was 57.89% (95% CI=26.79, 75.79) and was 61.35% (95% CI=35.33, 76.91) among carriers of HLA-B15.

Keywords: AIDS; HIV; HLA; Immune response; Oman; cART.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology*
  • Adult
  • Alleles
  • Antiretroviral Therapy, Highly Active*
  • Female
  • Genetic Association Studies
  • Genotype
  • HIV-1*
  • HLA-A Antigens / genetics*
  • HLA-B15 Antigen / genetics*
  • Humans
  • Immunity, Cellular / genetics*
  • Male
  • Middle Aged
  • Treatment Outcome
  • Viral Load

Substances

  • HLA-A Antigens
  • HLA-B15 Antigen